This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
EBioMedicine, 26, 78-90
Citation
Daveson, A James M; Ee, Hooi C; Andrews, Jane M; King, Timothy; Goldstein, Kaela E; Dzuris, John L; MacDougall, James A; Williams, Leslie J; Treohan, Anita; Cooreman, Michael P; Anderson, Robert P. (2017). Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.. EBioMedicine, 26, 78-90. https://doi.org/10.1016/j.ebiom.2017.11.018